Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience.

Details

Serval ID
serval:BIB_54721CC35333
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience.
Journal
Radiology. Imaging cancer
Author(s)
Brunsing R.L., Chen D.H., Schlein A., Wolfson T., Gamst A., Mamidipalli A., Violi N.V., Marks R.M., Taouli B., Loomba R., Kono Y., Sirlin C.B.
ISSN
2638-616X (Electronic)
ISSN-L
2638-616X
Publication state
Published
Issued date
11/2019
Peer-reviewed
Oui
Volume
1
Number
2
Pages
e190010
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
To describe a single-center preliminary experience with gadoxetate disodium-enhanced abbreviated MRI for hepatocellular carcinoma (HCC) screening and surveillance in patients with cirrhosis or chronic hepatitis B virus (cHBV).
This was a retrospective study of consecutive patients aged 18 years and older with cirrhosis or cHBV who underwent at least one gadoxetate-enhanced abbreviated MRI examination for HCC surveillance from 2014 through 2016. Examinations were interpreted prospectively by one of six abdominal radiologists for clinical care. Clinical, imaging, and other data were extracted from electronic medical records. Diagnostic adequacy was assessed in all patients. Diagnostic accuracy was assessed in the subset of patients who could be classified as having HCC or not having HCC on the basis of a composite reference standard.
In this study, 330 patients (93% with cirrhosis; 45% women; mean age, 59 years) underwent gadoxetate-enhanced abbreviated MRI. In the 330 patients, 311 (94.2%) baseline gadoxetate-enhanced abbreviated MRI examinations were diagnostically adequate. Of 141 (43%) of the 330 patients, 91.4% (129 of 141) could be classified as not having HCC and 8.6% (12 of 141) could be classified as having HCC. Baseline gadoxetate-enhanced abbreviated MRI had 0.92 sensitivity (95% confidence interval [CI]: 0.62, 1.00) and 0.91 specificity (95% CI: 0.84, 0.95) for detection of HCC. Of the 330 patients who underwent baseline gadoxetate-enhanced abbreviated MRI, 187 (57%) were lost to follow-up.
Gadoxetate-enhanced abbreviated MRI is feasible clinically, has a high diagnostic adequacy rate, and, on the basis of our preliminary experience, accurately depicts HCC in high-risk patients. Strategies to enhance follow-up compliance are needed.© RSNA, 2019Keywords: Abdomen/GI, Cirrhosis, Liver, MR-Imaging, Oncology, ScreeningSupplemental material is available for this article.
Keywords
Adult, Carcinoma, Hepatocellular/diagnostic imaging, Contrast Media, Female, Gadolinium DTPA, Hepatitis B, Chronic/diagnostic imaging, Humans, Image Enhancement/methods, Liver Cirrhosis/diagnostic imaging, Liver Neoplasms/diagnostic imaging, Magnetic Resonance Imaging/methods, Male, Middle Aged, Preliminary Data, Reference Standards, Retrospective Studies, Sensitivity and Specificity
Pubmed
Open Access
Yes
Create date
31/05/2021 14:59
Last modification date
06/09/2022 5:40
Usage data